Melatonin reduces neuroinflammation and ameliorates gut dysbiosis in the preclinical mouse model of progressive multiple sclerosis
Eduardo Ponce-España, Ana Isabel Álvarez-López, Ignacio Bejarano, Guillermo Santos-Sánchez, Ivan Cruz-Chamorro, Iván Parralejo-Ayala, Patricia Judith-Lardone, Antonio Carrillo-Vico · FENS Forum 2024
Multiple sclerosis (MS) is a chronic neurodegenerative disease that is the leading cause of disability in young adults. The most severe clinical form of MS is the primary progressive (PP). We and others have shown that melatonin (MLT), improves the disease modulating the immune response in the Experimental Autoimmune Encephalomyelitis (EAE) monofasic mouse model of MS. Thus, the objective of this study was to evaluate the therapeutic use of MLT in the neuroinflammation, neurodegeneration and gut dysbiosis in the preclinical model of MS-PP, the progressive EAE (p-EAE).p-EAE was induced in 10-we
ePoster · Neuroscience